16 Apr
0
This post was originally published on this site
Ketamine is emerging as a potential new drug for depression – the first of its kind in 35 years. Johnson & Johnson is actively pursuing a nasal formulation of the drug. Researchers plan to present the results of an advanced clinical trial of the formula next month at the American Psychiatric Association meeting.
More »